Overview

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol de Investigacion en Sarcomas
Collaborator:
Bayer